药物基因组学中的早期健康技术评估：心血管药物的一个案例
Early health technology assessments in pharmacogenomics: a case example in cardiovascular drugs.
作者信息
Geenen Joost W, Baranova Ekaterina V, Asselbergs Folkert W, de Boer Anthonius, Vreman Rick A, Palmer Colin Na, Maitland-van der Zee Anke H, Hövels Anke M
机构信息
Division of Pharmacoepidemiology & Clinical Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Faculty of Science, Utrecht University, PO Box 80082, 3508 TB Utrecht, The Netherlands.
Department of Cardiology, Division Heart & Lungs, UMC Utrecht, 3508 GA Utrecht, The Netherlands.
出版信息
Pharmacogenomics. 2017 Aug;18(12):1143-1153. doi: 10.2217/pgs-2017-0063. Epub 2017 Jul 26.
AIM
To assess the required characteristics (cost, sensitivity and specificity) of a pharmacogenomic test for being a cost-effective prevention of angiotensin-converting enzyme inhibitors induced angioedema. Furthermore, we assessed the influence of only testing high-risk populations.
MATERIALS & METHODS: A decision tree was used.
RESULTS
With a willingness-to-pay threshold of €20,000 and €80,000 per quality adjusted life year, a 100% sensitive and specific test may have a maximum cost of €1.30 and €1.95, respectively. When only genotyping high-risk populations, the maximum test price would be €5.03 and €7.55, respectively.
CONCLUSION
This theoretical pharmacogenomic test is only cost-effective at high specificity, high sensitivity and a low price. Only testing high-risk populations yields more realistic maximum test prices for cost-effectiveness of the intervention.
目的
评估药物基因组学检测作为一种具有成本效益的预防血管紧张素转换酶抑制剂所致血管性水肿的方法所需具备的特征（成本、敏感性和特异性）。此外，我们评估了仅对高危人群进行检测的影响。
材料与方法
使用决策树。
结果
在每质量调整生命年支付意愿阈值为20,000欧元和80,000欧元的情况下，100%敏感且特异的检测的最高成本分别可能为1.30欧元和1.95欧元。当仅对高危人群进行基因分型时，最高检测价格分别为5.03欧元和7.55欧元。
结论
这种理论上的药物基因组学检测仅在高特异性、高敏感性和低价格时才具有成本效益。仅对高危人群进行检测可为干预措施的成本效益得出更实际的最高检测价格。
Zotero 插件